Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

How to plan, execute and refine an excellent congress experience

Medical congresses are one of the most important and intensive marketing activities a company can undertake. Here, Account Director Dolan Desai and Senior Creative Copywriter Dale Choate give you the...

Blue Latitude Health

- PMLiVE

Shire claims FDA approval for slow-cooked ADHD drug

Mydayis will reach the US market in the third quarter of the year

- PMLiVE

GSK makes case for revaccination with Shingrix

The pharma giant seeks regulatory approval to treat people aged 50 plus

Sanofi continues pharma’s trend of ditching the corporate blog

Will integrate Speaking of Sanofi content into its main US website

- PMLiVE

FDA panel backs CV claims for Novo Nordisk’s Victoza

LEADER trial shows the diabetes treatment reduces risk of cardiovascular death by 13%

- PMLiVE

Warning sounded on pharma’s long-term sales prospects

Analysts at EvaluatePharma downgrade their projections in face of pricing pressures and biosimilar competition

- PMLiVE

Lilly and NRAS launch arthritis awareness film campaign

Pharma firm's ‘Behind The Smile’ initiative coincides with RA awareness week

- PMLiVE

IGEM Therapeutics appoints Dr Tim Wilson as CEO

He joins after the UK immuno-oncology firm raises £2m to advance its pipeline

- PMLiVE

Smart solutions

How technology could help pharma breathe new life into branded respiratory drugs

How can pharma help the NHS capitalise on its data?

Sue Thomas, Paul Midgley and Steve How, of Wilmington Healthcare, explain how pharma can work with the NHS to transform services

Wilmington Healthcare

- PMLiVE

Facing the new wave of biosimilars

Don’t drown out the patient voice, says advocacy group

- PMLiVE

21st Century Cures Act: a commercial perspective on how the new FDA regulation could revolutionise use of RWE and analytics in healthcare

The 21st Century Cures Act has transformed the US drug development landscape. David Cooney explores the implications of the Act for pharmaceutical companies and reveals how it can be leveraged.

Blue Latitude Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links